开云app官网登录入口网页版-官方正版

#SGLT#

125篇内容 | 2141人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793890, encodeId=da0b1e938907a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=74, createdTime=2022-12-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793886, encodeId=a4a71e93886cd, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=82, createdTime=2023-06-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793883, encodeId=220b1e9388320, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, objectType=article, longId=735642, objectId=ed39e3564211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed39e3564211, replyNumber=0, likeNumber=147, createdTime=2023-07-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed39e3564211, moduleTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ed39e3564211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793888, encodeId=f7651e93888a9, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, objectType=article, longId=737027, objectId=7b6ee370276e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b6ee370276e, replyNumber=0, likeNumber=69, createdTime=2022-12-27, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6ee370276e, moduleTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b6ee370276e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793889, encodeId=4bf21e9388966, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, objectType=article, longId=737405, objectId=2c50e37405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c50e37405f8, replyNumber=0, likeNumber=84, createdTime=2022-09-26, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c50e37405f8, moduleTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2c50e37405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793885, encodeId=80a71e938854e, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, objectType=article, longId=736137, objectId=47e3e3613704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e3e3613704, replyNumber=0, likeNumber=92, createdTime=2023-02-14, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e3e3613704, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47e3e3613704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793881, encodeId=41671e93881a6, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=eClinicalMed：SGLT2i对2型糖尿病患者肾脏功能的保护作用更胜一筹！, objectType=article, longId=730605, objectId=ea33e3060501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea33e3060501, replyNumber=0, likeNumber=103, createdTime=2023-02-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea33e3060501, moduleTitle=eClinicalMed：SGLT2i对2型糖尿病患者肾脏功能的保护作用更胜一筹！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea33e3060501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793873, encodeId=5ad41e93873fd, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=79, createdTime=2022-10-07, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793882, encodeId=98281e93882d9, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Circulation：SGLT2和血管紧张素转换酶抑制剂联合治疗对肾脏和血管的影响, objectType=article, longId=732271, objectId=8eb7e3227136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eb7e3227136, replyNumber=0, likeNumber=82, createdTime=2023-02-03, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eb7e3227136, moduleTitle=Circulation：SGLT2和血管紧张素转换酶抑制剂联合治疗对肾脏和血管的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8eb7e3227136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793878, encodeId=08d21e9387875, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, objectType=article, longId=723949, objectId=4428e2394910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4428e2394910, replyNumber=0, likeNumber=91, createdTime=2022-12-19, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4428e2394910, moduleTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4428e2394910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793872, encodeId=13241e9387212, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, objectType=article, longId=295380, objectId=927829538021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=927829538021, replyNumber=0, likeNumber=91, createdTime=2022-02-14, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=927829538021, moduleTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=927829538021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793874, encodeId=9bd51e93874da, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JCEM：恩格列净和肾结石风险降低：SGLT2抑制的潜在新作用？, objectType=article, longId=301458, objectId=d30630145875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d30630145875, replyNumber=0, likeNumber=83, createdTime=2022-11-30, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d30630145875, moduleTitle=JCEM：恩格列净和肾结石风险降低：SGLT2抑制的潜在新作用？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d30630145875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793871, encodeId=5de31e93871f4, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, objectType=article, longId=292226, objectId=5d56292226bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d56292226bc, replyNumber=0, likeNumber=83, createdTime=2022-11-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d56292226bc, moduleTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5d56292226bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793887, encodeId=91771e938878d, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, objectType=article, longId=736722, objectId=3a36e36722e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a36e36722e3, replyNumber=0, likeNumber=93, createdTime=2023-07-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a36e36722e3, moduleTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3a36e36722e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793880, encodeId=6bfa1e9388019, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响, objectType=article, longId=727305, objectId=fc4be2730555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc4be2730555, replyNumber=0, likeNumber=90, createdTime=2022-08-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc4be2730555, moduleTitle=Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc4be2730555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793879, encodeId=1c6e1e93879d8, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, objectType=article, longId=725589, objectId=2d1de25589ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d1de25589ae, replyNumber=0, likeNumber=92, createdTime=2023-02-12, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d1de25589ae, moduleTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d1de25589ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793884, encodeId=22761e9388433, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, objectType=article, longId=736106, objectId=5cc6e3610606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc6e3610606, replyNumber=0, likeNumber=69, createdTime=2023-02-26, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc6e3610606, moduleTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5cc6e3610606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793877, encodeId=624a1e93877b0, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=113, createdTime=2023-03-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793869, encodeId=9bc51e93869db, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系, objectType=article, longId=220869, objectId=83b52208691b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83b52208691b, replyNumber=0, likeNumber=80, createdTime=2022-05-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83b52208691b, moduleTitle=JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=83b52208691b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793866, encodeId=97191e93866b9, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, objectType=article, longId=219643, objectId=0933219643a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933219643a0, replyNumber=0, likeNumber=128, createdTime=2022-09-29, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933219643a0, moduleTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0933219643a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

SGLT

2020-05-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2022-12-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2023-06-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险

2023-07-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险

2022-12-27

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭

2022-09-26

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况

2023-02-14

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

eClinicalMed：SGLT2i对2型糖尿病患者肾脏功能的保护作用更胜一筹！

2023-02-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-10-07

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Circulation：SGLT2和血管紧张素转换酶抑制剂联合治疗对肾脏和血管的影响

2023-02-03

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险

2022-12-19

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较

2022-02-14

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JCEM：恩格列净和肾结石风险降低：SGLT2抑制的潜在新作用？

2022-11-30

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！

2022-11-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险

2023-07-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响

2022-08-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系

2023-02-12

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素

2023-02-26

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2023-03-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系

2022-05-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响

2022-09-29

科室
- - 订阅+
  - 更多科室
工具
服务